Potential new therapies for the treatment of HIV-1 infection

被引:33
作者
Condra, JH [1 ]
Miller, MD [1 ]
Hazuda, DJ [1 ]
Emini, EA [1 ]
机构
[1] Merck Res Labs, West Point, PA 19486 USA
来源
ANNUAL REVIEW OF MEDICINE | 2002年 / 53卷
关键词
protease; reverse transcriptase; integrase; entry inhibitors; assembly inhibitors;
D O I
10.1146/annurev.med.53.082901.104110
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The development and clinical use of chemotherapeutic agents for the treatment of persistent HIV-1 infection over the past decade has profoundly and favorably affected the course of HIV-1 disease for many infected individuals. Unfortunately, the long-term use of these therapies is complicated by unwanted metabolic side effects, by issues of adherence, and by the selection of viral variants with reduced susceptibility. These complications have spurred the search for new anti-HIV-1 agents having improved pharmacological properties and expressing activity against viral variants resistant to the currently available agents. This brief review describes the current state of this search as well as potentially novel viral targets for chemotherapeutic intervention.
引用
收藏
页码:541 / 555
页数:15
相关论文
共 76 条
[11]   A SPRING-LOADED MECHANISM FOR THE CONFORMATIONAL CHANGE OF INFLUENZA HEMAGGLUTININ [J].
CARR, CM ;
KIM, PS .
CELL, 1993, 73 (04) :823-832
[12]   Core structure of gp41 from the HIV envelope glycoprotein [J].
Chan, DC ;
Fass, D ;
Berger, JM ;
Kim, PS .
CELL, 1997, 89 (02) :263-273
[13]   HIV entry and its inhibition [J].
Chan, DC ;
Kim, PS .
CELL, 1998, 93 (05) :681-684
[14]   Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors [J].
Corbett, JW ;
Ko, SS ;
Rodgers, JD ;
Gearhart, LA ;
Magnus, NA ;
Bacheler, LT ;
Diamond, S ;
Jeffrey, S ;
Klabe, RM ;
Cordova, BC ;
Garber, S ;
Logue, K ;
Trainor, GL ;
Anderson, PS ;
Erickson-Viitanen, SK .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (10) :2019-2030
[15]   Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry [J].
Datema, R ;
Rabin, L ;
Hincenbergs, M ;
Moreno, MB ;
Warren, S ;
Linquist, V ;
Rosenwirth, B ;
Seifert, J ;
McCune, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :750-754
[16]   HIGHLY POTENT AND SELECTIVE-INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS BY THE BICYCLAM DERIVATIVE JM3100 [J].
DE CLERCQ, E ;
YAMAMOTO, N ;
PAUWELS, R ;
BALZARINI, J ;
WITVROUW, M ;
DEVREESE, K ;
DEBYSER, Z ;
ROSENWIRTH, B ;
PEICHL, P ;
DATEMA, R ;
THORNTON, D ;
SKERLJ, R ;
GAUL, F ;
PADMANABHAN, S ;
BRIDGER, G ;
HENSON, G ;
ABRAMS, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :668-674
[17]  
DEBETHUNE MP, 2001, ANTIVIR THER, V6, P6
[18]   AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor [J].
Donzella, GA ;
Schols, D ;
Lin, SW ;
Esté, JA ;
Nagashima, KA ;
Maddon, PJ ;
Allaway, GP ;
Sakmar, TP ;
Henson, G ;
De Clercq, E ;
Moore, JP .
NATURE MEDICINE, 1998, 4 (01) :72-77
[19]   A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor [J].
Doranz, BJ ;
GrovitFerbas, K ;
Sharron, MP ;
Mao, SH ;
Goetz, MB ;
Daar, ES ;
Doms, RW ;
OBrien, WA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (08) :1395-1400
[20]   Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes [J].
Dorn, CP ;
Finke, PE ;
Oates, B ;
Budhu, RJ ;
Mills, SG ;
MacCoss, M ;
Malkowitz, L ;
Springer, MS ;
Daugherty, BL ;
Gould, SL ;
DeMartino, JA ;
Siciliano, SJ ;
Carella, A ;
Carver, G ;
Holmes, K ;
Danzeisen, R ;
Hazuda, D ;
Kessler, J ;
Lineberger, J ;
Miller, M ;
Schleif, WA ;
Emini, EA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) :259-264